Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation

A PRISMA-compliant article

Yashi Ruan, MD, Wei Guo, MD, Sudong Liang, MD, Zhen Xu, MD, Tianli Niu, MD

Abstract

Background: Cytomegalovirus (CMV) infection is part of major infection complications following kidney transplantation. However, more rapid and low-complexity assays are needed for CMV infection. Our study is to investigate the diagnostic efficacy of 2 novel tests, CMV-ELISPOT and QuantiFERON-CMV tests, in CMV DNA viremia and CMV infection following renal transplant.

Methods: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and the Web of Science. Case-control or cohort study designed to explore the CMV-ELISPOT and/or QuantiFERON-CMV tests in the recipients with CMV infection was considered to be eligible for this study. Sensitivity (SEN), specificity (SPE), diagnostic odds ratio (DOR), and summary receiver-operating characteristic (SROC) curves were calculated.

Results: We selected a total of 12 articles for systematic review and 11 of them were included in meta-analysis. For CMV-pp65 assay, the pooled SEN, SPE, and DOR were 0.73 (95% confidence interval [CI], 0.67–0.78), 0.61 (95% CI, 0.56–0.65), and 4.46 (95% CI, 3.11–6.39), respectively. For CMV-IE-1 assay, the pooled SEN, SPE, and DOR were 0.84 (95% CI, 0.78–0.88), 0.46 (95% CI, 0.42–0.51), and 5.07 (95% CI, 3.26–7.89), respectively, whereas the pooled SEN, SPE, and DOR of QuantiFERON-CMV test were 0.38 (95% CI, 0.28–0.49), 0.38 (95% CI, 0.32–0.44), and 1.02 (95% CI, 0.17–6.00).

Conclusions: We reported that CMV-ELISPOT tests, including CMV-pp65 and CMV-IE-1, perform well in the diagnosis and prediction of CMV infection in renal transplant recipients, whereas QuantiFERON-CMV test needs further exploration.

Abbreviations: CENTRAL = the Cochrane Central Register of Controlled Trials, CIs = confidence intervals, CMV = cytomegalovirus, DOR = diagnostic odds ratios, ELISA = enzyme-linked immunosorbent assay, FCM = flow cytometry, FN = false negatives, FP = false positives, HLA = human leukocyte antigen, IE-1 = immediate early 1, IFN-γ = interferon-gamma, NLR = negative likelihood ratios, PLR = positive likelihood ratios, pp65 = phosphoprotein 65, SEN = sensitivity, SPE = specificity, TN = true negatives, TP = true positives, WOS = Web of Science.

Keywords: cytomegalovirus, immune monitoring, kidney transplantation, meta-analysis, systematic review

1. Introduction

Although remarkable improvements in the management and treatment of cytomegalovirus (CMV) infection have been achieved, human CMV infection still remains to be one of major infection complications following kidney transplantation. In renal transplant recipients, CMV-mediated indirect effects on organ damage include chronic allograft nephropathy and allograft rejection. Among these renal donors and allograft recipients, seropositivity has been recognized as a biomarker for latent CMV infection. Recipients with highest risk of CMV infection are the combination of a CMV seronegative recipient and a CMV seropositive donor (D+/R−), which represent 15% to 25% in all renal transplant recipients. Moreover, 5% of CMV seronegative recipients with CMV seronegative donors (D−/R−) also suffer from posttransplant CMV infection, mainly due to the social contacts and blood transfusion. Thus, accurate identification of the risks of renal transplant recipients with CMV infection is still urgently needed in clinical practice.

In recent years, several studies reported that the recovery of CMV-specific CD4+ and CD8+ T cells is related to the long-term protection from CMV reactivation and viremia, and reduced CMV-mediated damage. Therefore, monitoring the CMV-specific cellular immunity has been investigated to better predict the risk of CMV infection among recipients. In general, the most commonly used diagnostic tools based on the principle of CMV-specific cellular immunity include CMV enzyme-linked immunospot (ELISPOT) assays and QuantiFERON-CMV test.
The T-cell immune activity of former one could be measured by assessing the interferon-gamma (IFN-γ) production after the stimulation with CMV antigens such as phosphoprotein 65 (pp65) and immediate early 1 (IE-1), whereas the latter one is an enzyme-linked immunosorbent assay (ELISA) tool to test the released levels of IFN-γ in the whole blood by ex vivo stimulation with human leukocyte antigen (HLA) class I-restricted CMV peptides. However, controversial conclusions with regard to these novel technologies were observed across studies.

In our study, we performed the comprehensive systematic review to compare various studies investigating the CMV ELISPOT and/or QuantiFERON-CMV assays, and carried out the meta-analysis to quantitatively evaluate the diagnostic performance of these assays in CMV DNA viremia and infection following kidney transplantation.

2. Methods and materials

2.1. Ethics statement

The protocols followed in this study were in accordance with the ethical standards of the Declarations of Helsinki and Istanbul, and approved by the local ethics committee of Taizhou People’s Hospital.

2.2. Search strategy

The following databases were comprehensively searched for studies published between January 1, 1990 and February 1, 2018: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science (WOS). The search was performed using the following search keywords in combination: (“CMV” OR “cytomegalovirus”) AND (“Enzyme-Linked Immunosorbent Assay” OR “ELISPOT” OR “QuantiFERON” OR “QF”) AND (“kidney transplantation” [MeSH]). In addition, the reference lists of all articles in eligible studies were also read to identify any additional relevant literature.

2.3. Inclusive and exclusive criteria

Eligible studies have to meet the following criteria: case–control or cohort study with prospective or retrospective; sufficient data for pooled analysis (true positives [TP], true negatives [TN], false positives [FP], and false negatives [FN]) to predict viremia; if data or subsets of data were used in series trials, the more recent article, or the one with more detail was chosen; and articles written in English or Chinese. The exclusion criteria included the following: reviews, case reports, and letters to editors; duplicate publications; studies in languages other than English or Chinese; and studies with insufficient data to construct a 2 × 2 table. Two reviewers (YSR and WG) independently reviewed the eligible studies. Consensus was reached for each eligible study and any disagreements were resolved by consultation with a third reviewer (TLN).

2.4. Data extraction and management

Two authors (YSR and WG) independently extracted data for all eligible studies, including author, publication year, study design, number of participants included, ethnicity, male/female, average age, positive predictive and negative predictive value, PPV and NPV, predictive values of DNA viremia of CMV ELISPOT assay, or QuantiFERON-CMV test.

2.5. Quality assessment

We used the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2) to evaluate the risk of bias in 4 domains, which included participant selection, index test, reference standard, as well as flow and timing. According to the QUADAS-2 guidelines, 2 authors (YSR and WG) assessed risk of bias for these 4 domains as low, high, or unclear. In case of disagreement, we resolved by discussion with a third author (TLN).

2.6. Statistical analysis

The meta-analysis was carried out by pooling the sensitivity (SEN), specificity (SPE), positive likelihood ratios (PLR), negative likelihood ratios (NLR), and diagnostic odds ratios (DOR) with random effects models and their 95% confidence intervals (CIs) for the overall CMV tests, CMV-IE-1, CMV-pp65, and QuantiFERON-CMV tests, to evaluate the risk of DNA viremia. Moreover, the corresponding summary receiver-operating characteristic (ROC) curves were calculated to express the test parameter results. The AUC-ROCs were always close to 1 when a test was accurate, and in contrast, poor tests usually had an AUC-ROC approaching 0.5.

In addition, heterogeneity among these studies was quantitatively assessed with the inconsistency index (I²), which indicated substantial heterogeneity if the value of I² was >50%. We calculated Spearman’s correlation coefficient to assess the potential threshold effect. All of the statistical analyses were conducted using Meta-Disc software (version 1.4; the Ramón y Cajal Hospital, Madrid, Spain).

3. Results

3.1. Study selection and basic characteristics

We identified a total of 25 studies after the original literature search (Fig. 1). After screening the titles and abstracts, 6 studies were deleted according to the exclusive criteria. In general, 12 studies were included in our systematic review, and 11 of which were selected for quantitative analysis.

The results of systematic review are presented in Table 1. The primary outcomes of all eligible studies in our study were the diagnostic accuracy of CMV-ELISPOT and/or QuantiFERON-CMV tests, including SEN and SPE, to predict CMV DNA viremia. Nine of 10 studies were carried out in the ethnicity of Caucasian, and 1 study was carried out in Asians. Seven studies evaluated the CMV-pp65 assay, 6 studies evaluated the CMV-IE-1 assay, and 4 studies evaluated the QuantiFERON-CMV test. Importantly, there were 6 studies reported the administration of prophylactic treatment for CMV (+) recipients, and our results of meta-regression analysis did not support the significant impact of prophylactic treatment on the pooled results. The results of quality assessment across studies are shown in Figure 2. The majority of included studies clearly stated the aspects related to 4 domains in QUADAS-2, indicating the overall quality is moderate–high. Moreover, there is no disagreement during the study selection, data extraction, and quality assessment.

3.2. Diagnostic accuracy of CMV ELISPOT and QuantiFERON-CMV tests

Eleven studies with 1167 renal transplant recipients were enrolled in the meta-analysis for all 3 tests (CMV-pp65, CMV-IE-1, and
QuantiFERON-CMV). First, we evaluated the threshold effects in the pooled data, and the results showed that Spearman correlation coefficient and its P value were 0.43 and 0.067, which suggested no significant threshold effect exists. The pooled SEN and SPE estimates were 0.72 (95% CI, 0.68–0.76) and 0.50 (95% CI, 0.47–0.53) to predict CMV DNA viremia, respectively (Fig. 3A and B). The pooled PLR and NLR estimates were 1.54 (95% CI, 1.32–1.81) and 0.47 (95% CI, 0.32–0.69) (Supplemental Fig. 1A and B, http://links.lww.com/MD/C923), whereas the pooled DOR estimates were 4.02 (95% CI, 2.18–7.40) (Fig. 3C). The AUC estimates of SROC curve were 0.70 (Fig. 3D). Significant heterogeneity was observed in both pooled SEN ($I^2 = 87.3\%$, $P < 0.001$) and SPE ($I^2 = 91.0\%$, $P < 0.001$), and then the random effects model was selected for further analysis. To explore the sources of extreme heterogeneity, we performed the meta-regression based on 2 potential confounding factors, including the ethnicity and methods. The results showed that test methods were significantly associated with relatively high heterogeneity, indicating the subgroup analysis of individual CMV diagnostic methods is necessary (coefficient: 0.94, $P = 0.017$; Supplemental Table 1, http://links.lww.com/MD/C923).

Six clinical trials were included in the meta-analysis for CMV-pp65 assay. The pooled SEN and SPE estimates were 0.73 (95% CI, 0.67–0.78) and 0.61 (95% CI, 0.56–0.65), respectively (Fig. 4A and B). The pooled PLR and NLR estimates were 1.83 (95% CI, 1.47–2.27) and 0.44 (95% CI, 0.32–0.61) (Supplemental Fig. 1C and D, http://links.lww.com/MD/C923), whereas the pooled DOR estimates were 4.46 (95% CI, 3.11–6.39) (Fig. 4C). The AUC estimates of SROC curve were 0.73 (Fig. 4D).

Likely, 6 clinical trials were included in the meta-analysis for CMV-IE-1 assay. The pooled SEN and SPE estimates were 0.84 (95% CI, 0.78–0.88) and 0.46 (95% CI, 0.42–0.51), respectively

Figure 1. PRISMA flow diagram.
Table 1

| Author (publication year) | Ethnicity | Case no. | CMV prophylactic treatment | CMV test methods | Tests time points | Conclusion |
|---------------------------|-----------|----------|----------------------------|------------------|------------------|------------|
| P. Nickel (2009)          | Caucasian | 36       | No CMV prophylaxis         | CMV-IE1          | Pretransplantation, +1 d, +1, +2, +4 wk and +2, +3–6 mo | No evidence for heterologous immunity could be found in patients with high levels of CMV-specific T cells. |
| A. Lochmanova (2010)      | Caucasian | 14       | Not mentioned              | QuantIFERON      | Pretransplantation | The Quantiferon-CMV assay seems to be a sensitive specific test to detect a virus-specific T-cell response. |
| D. Abate (2013)           | Caucasian | 120      | Valganciclovir for 3 m in D+/R− cases | CMV-pp65, QuantiFERON | +30, +60, +90, +180, and +360 d | Monitoring IE-1-specific T-cell responses before transplantation may be useful for predicting posttransplant risk of CMV infection. |
| M. Rittà (2015)           | Caucasian | 80       | Prophylaxis for 3 mo in D+/R− cases | CMV-pp65, CMV-IE1 | Pretransplantation | The 2 tests displayed similar abilities for predicting CMV infection, and require several ameliorations to avoid false-negative results. |
| A. Tarasewicz (2016)      | Caucasian | 25       | Not mentioned              | QuantIFERON      | Once at a mean of 4.38 ± 2.73 mo after transplantation | The Quantiferon-CMV assay seems to be a useful tool in clinical practice, identifying the group of KTRs with increased risk of infectious complications. |
| F. Leone (2016)           | Caucasian | 40       | No CMV prophylaxis         | CMV-pp65, CMV-IE1 | +30, +90, +180, and +360 d | Monitoring CMV ELISPOT and eGFR in the first month posttransplant can identify patients at high risk of CMV infection, for whom preemptive antiviral therapy is recommended. |
| T. Schachtner (2017)      | Caucasian | 67 (D+/R−) | Valganciclovir for 3 m in D+/R− cases | CMV-pp65, CMV-IE1 | Pretransplantation, at +1, +2, and +3 mo | CMV ELISPOT from pretransplantation to posttransplantation, particularly CMV-IE1, offers superior risk stratification compared with CMV serostatus alone. |
| H. Lee (2017)             | Asian     | 124      | No CMV prophylaxis         | CMV-pp65, CMV-IE1, QuantiFERON | Pretransplant, +1, +3 mo | CMV ELISPOT at posttransplant 1 month can identify the risk of CMV viremia in serosensitive kidney transplant recipients. |
| J. Kwon (2017)            | Asian     | 47       | No CMV prophylaxis         | CMV-pp65, CMV-IE1, QuantiFERON | +1 mo, biweekly during the first and third months, and monthly to 6 mo | CMV ELISPOT assay predicted infection after operation better than the commercial IFN-γ-releasing assay. |

CMV = cytomegalovirus, ELISPOT = enzyme-linked immunospot, IFN-γ = interferon-gamma, D+/R− = CMV seropositive recipients with seronegative allografts, R+, CMV seropositive recipients, D−/R− = CMV seronegative recipients with seropositive allografts, NA, not available.

(Fig. 5A and B). The pooled PLR and NLR estimates were 1.54 (95% CI, 1.30–1.82) and 0.39 (95% CI, 0.25–0.60) (Supplemental Fig. 1E and F, http://links.lww.com/MD/C923), whereas the pooled DOR estimates were 5.07 (95% CI, 3.26–7.89) (Fig. 5C). The AUC estimates of SROC curve were 0.75 (Fig. 5D). Four studies were eligible for quantitative analysis of QuantiFERON-CMV test. The results showed that the pooled SEN and SPE estimates were 0.38 (95% CI, 0.28–0.49) and 0.38 (95% CI, 0.32–0.44) (Supplemental Fig. 2A and B, http://links.lww.com/MD/C923). The pooled PLR and NLR estimates were...
1.00 (95% CI, 0.40–2.48) and 1.11 (95% CI, 0.47–2.58) (Supplemental Fig. 2C and D, http://links.lww.com/MD/C923), whereas the pooled DOR estimates were 1.02 (95% CI, 0.17–6.00) (Supplemental Fig. 2E, http://links.lww.com/MD/C923). The AUC estimates of SROC curve were 0.41 (Supplemental Fig. 2F, http://links.lww.com/MD/C923).

4. Discussion
This is the first study in English literature to perform a systematic review and meta-analysis of the predictive utility of CMV-immune monitoring assays in kidney transplantation. In this study, we reported that CMV-ELISPOT tests, including CMV-pp65 and CMV-IE-1, perform well in the prediction of CMV...
infection in renal transplant recipients, whereas QuantiFERON-CMV test needs further exploration.

In the systematic review, favorable conclusions for CMV ELISPOT assays were observed, whereas one study\cite{22} reported no difference in CMV-specific T-cell frequencies between recipients with or without detectable CMV antibodies. However, the authors also found that strong CMV-IE-1-specific T-cells response were significantly associated with the less alloreactivity.

---

Figure 4. Results of diagnostic meta-analysis for CMV-pp65 assay in kidney transplantation, including the pooled sensitivity (A), specificity (B), diagnostic odds ratio (C), and SROC curve (D).

Figure 5. Results of diagnostic meta-analysis for CMV-IE-1 assay in kidney transplantation, including the pooled sensitivity (A), specificity (B), diagnostic odds ratio (C), and SROC curve (D).
and improved graft function, indicating that CMV-IE-1-specific T-cells response, which underlined the importance of IE-1 as a target of anti-CMV T cells and were consistent with previous studies.[28,29] Notably, CMV-pp65/IE-1 IFN-γCD8+ and CD4+ T cells enumerated by flow cytometry (FCM) has been explored to investigate the dynamics of CMV-specific T-cells immunity in several transplant centers.[30–32] Among eligible studies in systematic review, the usage of target peptide and methodology may be 2 major confounding factors resulting in the inconsistent conclusions. Two classic peptides, including CMV-pp65 and CMV-IE-1, were utilized to duplicate wells or selectively solo well in ELISPOT assay, and no study reported the difference between these 2 target peptides in the outcomes of assays.[33] Although comparisons of CMV-pp65/IE-1 between ELISPOT and FCM still need further confirmation, it does provide a novel insight to predict the CMV infections in solid organ transplantation.

The results of our meta-analysis did not support the application of QuantiFERON-CMV test in the prediction of CMV infection in renal transplant recipients. It is reported that CMV seropositive recipients with negative cellular mediated immunity tended to be positive in the QuantiFERON-CMV test when stimulated with non-HLA-restricted whole CMV virion lysate, which suggested the potential limitation of the stimuli used in the QuantiFERON-CMV test.[17] Moreover, the immune system would be dynamic when interplayed with positive and negative regulatory mechanisms across recipients and allograft, affecting both the recipient’s response and the underlying clinical conditions.[31,34,35] Consistent with these controversial results, our findings still suggested further efforts should be taken to promote the efficacy and utility of QuantiFERON-CMV test in kidney transplantation.

To be noted, it is often to observe the coexistence of CMV infection with the EBV (Epstein–Barr Virus) infection, and published reports showed the presence of cross-reactivity of EBV-specific IgM antibodies with CMV antigens, indicating that the EBV infection should be a crucial confounding factor of CMV-pp65/IE-1 and QuantiFERON-CMV tests.[36] Unfortunately, none of the included studies further explored the potential influence of EBV coinfection with CMV on the predictive efficacy. Furthermore, posttransplant lymphoproliferative disease (PTLD), mainly caused by EBV infection, required the additional intervention of intravenous immune globulin (IVIG), which inevitably contributed to the disturbances of the alloimmune responses, and then influenced the predictive efficacy of CMV-pp65/IE-1 and QuantiFERON-CMV assays.[37,38] For the improvement of the CMV-immune monitoring assays in kidney transplantation, great considerations should be taken to distinguish CMV infection with potential EBV infection.

Our study has several potential limitations. First, limited case numbers across included studies hindered our further exploration of the CMV-specific immune monitoring, such as subgroup analysis based on the donor and/or recipient CMV status. We hope to update our systematic review and meta-analysis in future, to account for novel studies that will emerge on the CMV ELISPOT and QuantiFERON-CMV tests. Then, we identified several sources of heterogeneity, including testing methods. However, some potential sources, such as selection bias, were ignored due to the lack of extracted information. Finally, the predictive efficacy of these tests during the administration of prophylactic treatments on the risk of CMV DNA viremia after the treatment still needed to be explored.

In conclusion, our systematic review and meta-analysis indicate that CMV-ELISPOT assays, including CMV-pp65 and IE-1, are potentially useful diagnostic tool for the prediction of CMV infection following kidney transplantation. On the contrary, our results suggested that great cautious should be taken for the use of the QuantiFERON-CMV test. Some contributions to promote the efficacy to predict CMV-specific T-cell immunity are urgent. Larger studies are needed to further characterize the utility of CMV immune monitoring system in clinical practice.

Author contributions
Conceptualization: Tianli Niu.
Data curation: Yashi Ruan, Wei Guo.
Formal analysis: Wei Guo.
Funding acquisition: Yashi Ruan.
Investigation: Tianli Niu.
Methodology: Yashi Ruan, Sudong Liang.
Project administration: Yashi Ruan.
Resources: Sudong Liang, Zhen Xu.
Software: Zhen Xu.
Supervision: Zhen Xu.
Visualization: Zhen Xu, Tianli Niu.
Writing – original draft: Yashi Ruan.
Writing – review and editing: Yashi Ruan.

References
[1] Noble J, Gatault P, Sautenet B, et al. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation. J Clin Virol 2017;99–100:38–43.
[2] Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation—challenging the status quo. Clin Transplant 2007;21:149–58.
[3] Fishman JA. Infection in renal transplant recipients. Semin Nephrol 2007;27:445–61.
[4] Humar A, Michaels M. Monitoring of Anti-CMV T cells immunity in transplant recipients with cytomegalovirus disease several years after transplantation. Am J Transplant 2006;6:262–74.
[5] Hudson EM, Ladhani M, Webster AC, et al. Antivirals for preventing cytomegalovirus disease in renal transplant recipients. Cochrane Database Syst Rev 2013;2:CD003774.
[6] Tu W, Potena L, Steppich-Biek P, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 2006;114:1608–15.
[7] Macek HT, Maino VC, Picker LJ. Immunofluorescence analysis of T-cell responses in health and disease. J Clin Immunol 2000;20:391–9.
[8] Cummins NW, Deziel PJ, Abraham RS, et al. Deficiency of cytomegalovirus (CMV)-specific CD8+ T-cells is associated with impaired T-cell response in patients with CMV disease. Transpl Infect Dis 2009;11:20–7.
[9] Chen P, Sun Q, Huang Y, et al. Blood dendritic cell levels associated with impaired IL-12 production and T-cell deficiency in patients with kidney disease: implications for post-transplant viral infections. Transpl Int 2014;27:1069–76.
[10] Lobo IA, Kumar D, Wilson LE, et al. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012;93:195–200.
[11] Kwon JS, Kim T, Kim SM, et al. Comparison of the commercial QuantiFERON-CMV and overlapping peptide-based ELISPOT assays for predicting CMV infection in kidney transplant recipients. Immune Netw 2017;17:317–23.
[12] Snyder LD, Chan C, Kwon D, et al. Polyclonal T-cell signatures to predict protection from cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 2016;193:78–85.
[13] Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.
[14] Moses LE, Shapero D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993;12:1293–316.

[15] Zamora J, Abraira V, Muriel A, et al. MetaDiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31.

[16] Schachtner T, Stein M, Reinke P. CMV-specific T cell monitoring offers superior risk stratification of CMV-seronegative kidney transplant recipients of a CMV-seropositive donor. Transplantation 2017;101:315–25.

[17] Abate D, Saldan A, Mengoli C, et al. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol 2013;51:2501–7.

[18] Lee H, Park KH, Ryu JH, et al. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients. PLoS One 2017;12:e0189488.

[19] Leone F, Gigliotti P, Mauro MV, et al. Early cytomegalovirus-specific T cell response and estimated glomerular filtration rate identify patients at high risk of infection after renal transplantation. Transpl Infect Dis 2016;18:191–201.

[20] Costa C, Balloco C, Sidoti F, et al. Evaluation of CMV-specific cellular immune response by ELISPOT assay in kidney transplant patients. J Clin Virol 2014;61:523–8.

[21] Abate D, Saldan A, Fiscon M, et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis 2010;202:585–94.

[22] Nickel P, Bold G, Presber F, et al. High levels of CMV-IE-1-specific memory T cells are associated with less allostimun and improved renal allograft function. Transplantation 2009;20:238–42.

[23] Lucia M, Crespo E, Melilli E, et al. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis 2014;59:1337–45.

[24] Ritta M, Costa C, Sidoti F, et al. Pre-transplant assessment of CMV-specific immune response by ELISPOT assay in kidney transplant recipients. New Microbiol 2015;38:329–35.

[25] Bestard O, Luca M, Crespo E, et al. Pretransplant immediately early-1 specific T cell responses provide protection for CMV infection after kidney transplantation. Am J Transplant 2013;13:1793–805.

[26] Taranowsa A, Debska-Sluzen A, Rutkowski B. Clinical utility of QuantiFERON-cytomegalovirus test in management of kidney transplant recipients. Transpl Proc 2016;48:1650–3.

[27] Lochmanova A, Lochman I, Tomaskova H, et al. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transpl Proc 2010;42:3574–7.

[28] Iwamoto GK, Konicek SA. Cytomegalovirus immediate early genes upregulate interleukin-6 gene expression. J Invest Med 1997;45:175–82.

[29] Crump JW, Geist LJ, Auron PE, et al. The immediate early genes of human cytomegalovirus require only proximal promoter elements to upregulate expression of interleukin-1 beta. Am J Respir Cell Mol Biol 1992;6:674–7.

[30] Corrales I, Solano C, Amat P, et al. IL28B genetic variation and cytomegalovirus-specific T-cell immunity in allogeneic stem cell transplant recipients. J Med Virol 2017;89:685–95.

[31] Gimenez E, Munoz-Cobo B, Solano C, et al. Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8+ T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantation. Transpl Infect Dis 2015;17:361–70.

[32] Gimenez E, Blanco-Lobo P, Munoz-Cobo B, et al. Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting. J Gen Virol 2015;96:2822–31.

[33] Nakamura A, Osonoi T, Terauchi Y. Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig 2010;1:208–11.

[34] Lang D, Vornhagen R, Rothe M, et al. Cross-reactivity of Epstein-Barr virus-specific immunoglobulin M antibodies with cytomegalovirus antigens containing glycine homopolymers. Clin Diagn Lab Immunol 2001;8:747–56.

[35] Nijland ML, Kersten MJ, Pals ST, et al. Epstein-Barr Virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management. Transplant Direct 2016;2:e48.

[36] Hasannia T, Moosavi Movahed SM, Vakili R, et al. Active CMV and EBV infections in renal transplant recipients with unexplained fever and elevated serum creatinine. Ren Fail 2016;38:1418–24.